Abstract
A nanoplatform targeting DNA and p53 simultaneously is assembled. Layered double hydroxide nanoparticles are co-loaded with a Pt(IV) prodrug and a p53 activator. Once inside cells, cisplatin is released to attack genomic DNA and kill cancer cells; simultaneously, the p53 activator results in active p53, a key protein involved in the apoptotic pathways initiated by platinum drugs. The anticancer efficacy of cisplatin is significantly improved through this synergistic application.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / chemistry
-
Antineoplastic Agents / pharmacology*
-
Apoptosis / drug effects
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Cisplatin / administration & dosage
-
Cisplatin / chemistry
-
Cisplatin / pharmacology*
-
Dose-Response Relationship, Drug
-
Drug Delivery Systems*
-
Drug Screening Assays, Antitumor
-
HeLa Cells
-
Humans
-
MCF-7 Cells
-
Mice
-
Organoplatinum Compounds / administration & dosage
-
Organoplatinum Compounds / chemistry
-
Organoplatinum Compounds / pharmacology*
-
Prodrugs / administration & dosage
-
Prodrugs / chemistry
-
Prodrugs / pharmacology*
-
Proto-Oncogene Proteins c-mdm2 / metabolism*
-
Structure-Activity Relationship
-
Tumor Suppressor Protein p53 / agonists*
-
Tumor Suppressor Protein p53 / metabolism
Substances
-
Antineoplastic Agents
-
Organoplatinum Compounds
-
Prodrugs
-
Tumor Suppressor Protein p53
-
Mdm2 protein, mouse
-
Proto-Oncogene Proteins c-mdm2
-
Cisplatin